Table 3.
Autoantibody profile in rheumatoid arthritis and psoriatic arthritis patients during etanercept treatment
| T0 weeks | T14 weeks | T22 weeks | T54 weeks | T102 weeks | ||
|---|---|---|---|---|---|---|
| RF-positive patients (%) | RA | 68·3 | 69·5 | 61·7 | 71·4 | 53 |
| PsA | 18·7 | 12·5 | 18·7 | 17·2 | 11·1 | |
| RF (IU/ml) | RA | 212·1 ± 461·4 | 201·2 ± 311·4 | 160 ± 296·5 | 174·6 ± 308·4 | 169·9 ± 263·8 |
| PsA | 17·3 ± 16·9 | 11·2 ± 4·5 | 12·22 ± 5·0 | 22·08 ± 39·12 | 11·13 ± 3·29 | |
| ACPA-positive patients (%) | RA | 79·3 | 73·2 | 74 | 64·2 | 68·2 |
| PsA | 0 | 3·1 | 0 | 6·8 | 0 | |
| APCA (IU/ml) | RA | 118·4 ± 126·7 | 136·4 ± 123·4 | 140·9 ± 123·7 | 134·9 ± 127·6 | 115·5 ± 112·7 |
| PsA | 3·18 ± 3·74 | 16·09 ± 52·28 | 10·15 ± 21·99 | 14·50 ± 41·18 | 3·97 ± 1·43 | |
| ANA-positive patients (%) | RA | 30·5 | 41·2 | 37 | 60a | 66·6a |
| PsA | 9·4 | 12·5 | 12·5 | 34·5a | 40·7a | |
| ENA-positive patients (%) | RA | 6·66 | 9·8 | 9·26 | 5·34 | 5·36 |
| PsA | 4·76 | 4·76 | 4·76 | 4·34 | 6·25 | |
| IgM–aCL positive patients (%) | RA | 6·35 | 6 | 5·55 | 6·2 | 6·23 |
| PsA | 3·12 | 3·12 | 6·25 | 6·25 | 0 | |
| IgG–aCL-positive patients (%) | RA | 0 | 0 | 0 | 4·44 | 4·16 |
| PsA | 0 | 0 | 0 | 0 | 0 |
Data are reported as mean ± standard deviation or the percentage of positive patients. Statistical analyses between nominal variables in rheumatoid arthritis and psoriatic arthritis patients were performed at all different time-points compared with T0 using χ2 test.
a
P < 0·05. aCL = anti-cardiolipin antibodies; ACP = anti-citrullinated protein antibodies; ANA = anti-nuclear antibodies; ENA = extractable nuclear antigens; Ig = immunoglobulin; PsA = psoriatic arthritis; RA = rheumatoid arthritis; RF = rheumatoid factor; T = time-point.